European Crohn’s and Colitis Organisation (ECCO) 2020

Patient-Reported Disease Activity in a Large Sample of Ulcerative Colitis (UC) Patients Using Social Media-Delivered Questionnaires

Pharmacokinetics and Circulating Total Lymphocyte Count Pharmacodynamic Response From Single and Multiple Oral Doses of Etrasimod in Japanese and Caucasian Healthy Male Subjects 

Fecal Calprotectin and C-Reactive Protein Levels Are Correlated With Long-Term Clinical and Endoscopic Outcomes: Analysis of the OASIS Open-Label Extension Trial of Etrasimod for Ulcerative Colitis 

AAPS PHARMSCI 360 Meeting 2019

Mass Balance, Metabolic Disposition, and Pharmacokinetics of [14C]Etrasimod Following Oral Administration to Healthy Male Volunteers

NASPGHAN 2019

Steady-State Trough Concentrations and Their Relationship to Selected Demographic and Clinical Response Measures in Etrasimod-Treated Patients With Moderately to Severely Active Ulcerative Colitis 

United European Gastroenterology Week 2019

Long-term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study 

Digestive Disease Week (DDW) 2019

Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis

Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations With Clinical Outcomes and Endoscopic Disease Activity in Patients With Ulcerative Colitis Receiving Induction Therapy With Etrasimod

Digestive Disease Week (DDW) 2019

Olorinab Reduces Visceral Hypersensitivity in Animal Models

Safety and Efficacy of Olorinab in Ph2a Study in Chronic Abdominal Pain Associated w-CD

14th Congress of European Crohn’s and Colitis Organisation (ECCO) 2019

Safety and Efficacy of Olorinab, a Peripherally Restricted, Highly-Selective, Cannabinoid Receptor 2 Agonist in a Phase 2a Study in Chronic Abdominal Pain Associated with Crohn’s Disease

1 2 3 4

For Medical Information, contact us at medinfo@arenapharm.com